个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共13条记录   Angiotensin II type 2 receptor agonists - where should they be applied? [作者：Steckelings, UM; Unger, T,期刊：Expert opinion on investigational drugs, 页码：763-766 , 文章类型： Editorial Material，,卷期：2012年21-6] It is now widely accepted that the renin-angiotensin system (RAS) not only contributes to pathological mechanisms involved, e. g. in hypertension or hypertensive and diabetic end-organ damage, but also harbors a "protect... Antibiotic prophylaxis in the era of multidrug-resistant bacteria [作者：Wittekamp, BHJ; Bonten, MJM,期刊：Expert opinion on investigational drugs, 页码：767-772 , 文章类型： Editorial Material，,卷期：2012年21-6] The prophylactic use of antibiotics can only be justified when clinical benefits on relevant patient outcomes, such as morbidity or mortality, cost-effectiveness, and absence of immediate emergence of antibiotic resistan... Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection [作者：Mackiewicz, A; Mackiewicz, J; Wysocki, PJ; Wiznerowicz, M; Kapcinska, M; Laciak, M; Rose-John, S; Izycki, D; Burzykowski, T; Karczewska-Dzionk, A,期刊：Expert opinion on investigational drugs, 页码：773-783 , 文章类型： Article，,卷期：2012年21-6] Objective: Two single arm, Phase II trials (3 and 5) were undertaken to determine the efficacy and toxicity of an adjuvant treatment using Hyper-IL-6 gene-modified whole-cell allogeneic melanoma vaccine in patients with ... Progress in the treatment of bone metastases in cancer patients [作者：Mackiewicz-Wysocka, M; Pankowska, M; Wysocki, PJ,期刊：Expert opinion on investigational drugs, 页码：785-795 , 文章类型： Review，,卷期：2012年21-6] Introduction: Bone metastases are a frequent complication of cancer, occurring in up to 70% of patients with advanced breast or prostate cancer. Skeletal-related events involving pathological fractures, spinal cord compr... Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9 [作者：Kowluru, RA; Zhong, Q; Santos, JM,期刊：Expert opinion on investigational drugs, 页码：797-805 , 文章类型： Review，,卷期：2012年21-6] Introduction: Diabetic retinopathy remains one of the most feared complications of diabetes. Despite extensive research in the field, the molecular mechanism responsible for the development of this slow progressing disea... CGRP receptor antagonists: an expanding drug class for acute migraine? [作者：Negro, A; Lionetto, L; Simmaco, M; Martelletti, P,期刊：Expert opinion on investigational drugs, 页码：807-818 , 文章类型： Review，,卷期：2012年21-6] Introduction: Migraine afflicts approximately 11% of the population worldwide producing substantial disability, resulting in loss of productivity both at home and at the workplace. Calcitonin gene-related peptide (CGRP) ... Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation [作者：Sanchez-Barcelo, EJ; Mediavilla, MD; Alonso-Gonzalez, C; Reiter, RJ,期刊：Expert opinion on investigational drugs, 页码：819-831 , 文章类型： Review，,卷期：2012年21-6] Introduction: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental invest... Anti-angiogenic therapies for malignant pleural mesothelioma [作者：Ceresoli, GL; Zucali, PA,期刊：Expert opinion on investigational drugs, 页码：833-844 , 文章类型： Review，,卷期：2012年21-6] Introduction: Malignant pleural mesothelioma (MPM) is a disease with a dismal prognosis. Currently available treatments have modest results. Therefore, new agents and new treatment strategies are eagerly awaited by patie... New therapeutic approaches to subarachnoid hemorrhage [作者：Barry, C; Turner, RJ; Corrigan, F; Vink, R,期刊：Expert opinion on investigational drugs, 页码：845-859 , 文章类型： Review，,卷期：2012年21-6] Introduction: Subarachnoid hemorrhage (SAH) is associated with significant morbidity and mortality, even for patients who receive early neurointerventionist management.Areas covered: Early mechanisms of secondary brain i... A potential role for nilotinib in KIT-mutated melanoma [作者：Tran, A; Tawbi, HA,期刊：Expert opinion on investigational drugs, 页码：861-869 , 文章类型： Editorial Material，,卷期：2012年21-6] Introduction: The advent of effective immunotherapy and targeted therapy, such as ipilimumab (anti-CTLA-4 monoclonal antibody) and vemurafenib (BRAF inhibitor), are changing the treatment paradigm for metastatic melanoma... Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia [作者：Thomas, X,期刊：Expert opinion on investigational drugs, 页码：871-878 , 文章类型： Editorial Material，,卷期：2012年21-6] Introduction: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 monoclonal antibody conjugated with calicheamicin. Preclinical data indicate activity against B-cell tumors and early results from clinical trials in... Regorafenib for cancer [作者：Strumberg, D; Schultheis, B,期刊：Expert opinion on investigational drugs, 页码：879-889 , 文章类型： Editorial Material，,卷期：2012年21-6] Introduction: Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-beta, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase.Areas covered: This review covers t... AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors [作者：Engel, J; Emons, G; Pinski, J; Schally, AV,期刊：Expert opinion on investigational drugs, 页码：891-899 , 文章类型： Editorial Material，,卷期：2012年21-6] Introduction: Receptors for the luteinizing hormone-releasing hormone [LHRH, also known as gonadotropin-releasing hormone (GnRH)] can be regarded as an ideal target for a personalized medicine approach in cancer therapy....